Showing results (251-260 of 357) with videos related to
Sort By:
Pageof 36
Cancer|March 15, 1996
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinomaE Wos, T Olencki, L Tuason, et al.Investigational New Drugs|May 1, 1993
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.The Annals of Thoracic Surgery|March 1, 1995
Expression of blood group antigen A by stage I non-small cell lung carcinomasT W Rice, R R Tubbs, G A Hoeltge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group StudyG E Goodman, J J Crowley, J C Blasko, et al.Journal of Biological Response Modifiers|December 1, 1990
Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effectsR M Bukowski, S Murthy, J Sergi, et al.Cancer|December 20, 2002
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignanciesTarek Mekhail, Thomas E Hutson, Paul Elson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trialR L Miller, R M Bukowski, G T Budd, et al.Cancer|February 15, 1992
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinomaR M Bukowski, G Inoshita, P Yalavarthi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effectsThomas E Hutson, Luis Molto, Tarek Mekhail, et al.Investigational New Drugs|August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumorsAndrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.Pageof 36